HOME Research Insight Market Leaders - Breast Cancer Liquid Biopsy Market



Market Leaders - Breast Cancer Liquid Biopsy Market


The global breast cancer liquid biopsy market is projected to reach USD 411.1 million by 2022 from USD 145.4 million in 2017, at a CAGR of 23.1%. The factors driving the growth of this market are the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

The breast cancer liquid biopsy market is a consolidated market with a large number of companies offering breast cancer liquid biopsy instruments and accessories. In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the breast cancer liquid biopsy market.

QIAGEN was the leading player in the breast cancer liquid biopsy market in 2017. The company is a global provider of sample-to-insight solutions that aids in the transformation of biological samples into molecular insights. The company operates through its two business segments, namely, instruments and consumables & related products. QIAGEN provides solutions to more than 500,000 customers globally, in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharma and biotech companies), and academia (life sciences research). The company operates in the breast cancer liquid biopsy market through its molecular diagnostics and life science tools customer base segment. .

To know the Insights download the pdf brochure

Roche Diagnostics ranked second in the breast cancer liquid biopsy market in 2017. Roche Diagnostics focuses on the discovery, manufacturing, and marketing of medical devices used to screen, diagnose, and monitor therapies. The company operates in the breast cancer liquid biopsy market through its molecular diagnostics segment. The company geographically operates in Europe, the Middle East and Africa, North America, Asia Pacific, and Latin America.

Illumina ranked third in the breast cancer liquid biopsy market in 2017. The company provides sequencing and array-based solutions for genetic analysis. The company develops, manufactures, and markets integrated systems and life science tools for the analysis of genetic variation and biological function. The company operates in the breast cancer liquid biopsy market through its spinoff company “GRAIL Inc.”.

Some of the major market players in the breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).

Related Reports:

Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports